Pulmonary thromboembolism in childhood: A single-center experience from Turkey

Tavil, Betül; Kuşkonmaz, Barış; Ki̇per, Nural; Çetin, Mualla; Gümrük, Fatma; Gürgey, Aytemiz

doi:10.1016/j.hrtlng.2007.06.004

Cited by 26 publications

(23 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is followed by initiation of antiviral agents like valganciclovir or ganciclovir and the use of an anticoagulation agent. So far, there has been no consensus on the choice of an anticoagulation agent and its duration, which is based mostly on the clinical decision of the treating physician [7, 8]. However, in our patient, anticoagulation therapy was initiated as the patient had venous thrombosis and we decided to continue the use of rivaroxaban at a dose of 15 mg PO twice daily for the initial 15 days followed by 20 mg PO once daily for six months.…”

Section: Discussionmentioning

confidence: 99%

Splenic Infarct and Pulmonary Embolism as a Rare Manifestation of Cytomegalovirus Infection

Rawla

Vellipuram

Bandaru

et al. 2017

Case Reports in Hematology

View full text Add to dashboard Cite

Cytomegalovirus (CMV) is a type of herpes infection that has a characteristic feature of maintaining lifelong latency within the host cell. CMV manifestations can cover a broad spectrum from fever to as severe as pancytopenia, hepatitis, retinitis, meningoencephalitis, Guillain-Barre syndrome, pneumonia, and thrombosis. Multiple case reports of thrombosis associated with CMV have been reported. Deep vein thrombosis or pulmonary embolism is more common in immunocompetent patients while splenic infarct is more common in immunocompromised patients. However, here we report a female patient on low-dose methotrexate for rheumatoid arthritis who presented with both pulmonary embolism and splenic infarct.

show abstract

Section: Discussionmentioning

confidence: 99%

Splenic Infarct and Pulmonary Embolism as a Rare Manifestation of Cytomegalovirus Infection

Rawla

Vellipuram

Bandaru

et al. 2017

Case Reports in Hematology

View full text Add to dashboard Cite

show abstract

“…Symptoms of PTE include dysfunction of the pulmonary circulation and respiration. [19,20] PTE is associated with high morbidity and mortality, with a poor prognosis. [21] PTE usually results from the activation, aggregation, and adhesion of platelets, which are regulated by certain genes.…”

Section: Discussionmentioning

confidence: 99%

PEAR1 gene polymorphism in a Chinese pedigree with pulmonary thromboembolism

Sun

Liang

et al. 2016

Medicine

View full text Add to dashboard Cite

To explore the correlation between platelet endothelial aggregation receptor-1 (PEAR1) genetic polymorphism and pulmonary thromboembolism (PTE).Variant loci of the PEAR1 gene were screened in a PTE pedigree, followed by verification using Sanger sequencing. These polymorphic loci were validated in 101 PTE patients and 132 matched normal patients using MassARRAY single nucleotide polymorphism (SNP) genotyping methods. The frequency differences between the allele and genotypes were compared using the Hardy–Weinberg equilibrium test and Chi-square test. The correlation between the PEAR1 gene SNP and PTE was analyzed by comparing the between-group variance differences using the χ2 test.Three SNPs were identified in the PTE pedigree. There was a heterozygous transition of T>C in rs1952294, and a transition of C>T in rs778026543 in 2 members in the pedigree; however, the rs778026543 was not identified in the 101 PTE patients and 132 healthy controls. The genotype and allele frequencies of rs822442 did not differ significantly between PTE patients and healthy controls (P > 0.05). The variance difference at rs778026543 between pedigree members and healthy controls was significant (P < 0.001), supporting its potential heredity.The PEAR1 polymorphism, rs778026543, but not rs1952294 and rs822442, may be a susceptibility SNP for PTE.

show abstract

“…Regarding the median age at the time of thrombosis diagnosis in children, Celkan et al reported a median age of 10 years, while Oren et al found this as 7 years, Tavil et al as 10.5 years 10,11,15 . The median age 288 of patients in our study was 5.1 years, which was significantly lower than the findings of other studies.…”

Section: Discussionmentioning

confidence: 99%

“…Pulmonary thromboembolism is usually associated with deep vein thrombosis. In most cases, pulmonary thromboembolism follows a clinically silent course and may be masked by the symptoms of the underlying disease 8,15,20,21 . On the other hand, four of our patients (8.2%) had pulmonary thromboembolism.…”

Section: Discussionmentioning

confidence: 99%

“…In a study by Alioglu et al, MTHFR 677CT mutation ranked first (28.8%), followed by FV Leiden (17.8%) and prothrombin 20210G mutations (5.8%) 14 . Tavil et al detected MTHFR 677CT mutation in 1 of the 16 patients diagnosed with pulmonary embolism (6.25%), FV Leiden mutation in 2 patients (12.5%) 15 . In a study by Ozbek et al, the MTHFR 677CT mutation was the most common with an incidence of 40.7%, respectively followed by FV Leiden mutation (14.1%) and prothrombin 20210GA mutation (4.4%) 7 .…”

Section: Risk Factors In Thrombosis Patientsmentioning

confidence: 99%

See 1 more Smart Citation